Cannabis · Hemp · Cultivation · Processing · Regulated Commerce · Public Policy
Cannabis Cultivation, Hemp & Regulated Markets Marketing Consultant & Advisor
The same genus can put a farmer, pharmacist, laboratory scientist, textile engineer, retailer, regulator, attorney, patient advocate and public-policy organization into the same conversation for completely different reasons.
Cannabis is agriculture, chemistry, manufacturing, medicine, regulated commerce, public policy and culture. I help lawful cannabis cultivators, medical marijuana treatment centers, dispensary organizations, hemp companies, processors, laboratories, genetics businesses, equipment and technology companies, trade associations, research organizations and related regulated-market operators turn complicated realities into clearer positioning, stronger authority and commercially useful growth.
Updated August 27, 2026
TL;DR
Cannabis is not one market, and the differences are commercially important.
Medical marijuana, adult-use marijuana, industrial hemp, cannabinoid research, a testing laboratory, a cultivation facility and a psilocybin clinical-development program can all sit near one another in public conversation while operating under very different legal, scientific and commercial systems.
The useful question is not simply, “How should cannabis be marketed?” It is: what is the lawful product, who may handle it, what evidence exists, who makes the buying decision, which channels are available, and what outcome would make the business stronger?
That is the work I do. I connect biology, regulation, production, evidence, customer or stakeholder behavior, digital authority and growth without pretending I am the attorney, physician, laboratory director, agronomist or regulator responsible for professional decisions outside my role.
Before Marketing Anything
Six questions change almost everything.
What is it?
Medical marijuana, adult-use marijuana, hemp, fiber, cannabinoid product, drug candidate, research program, ancillary technology or another regulated product.
Who regulates it?
Federal, state, tribal and local authority can overlap. The answer changes by product, jurisdiction and intended use.
Who may handle it?
Licenses, registrations, professional roles, testing requirements and facility permissions can determine who may cultivate, manufacture, dispense, research or sell.
How may it be sold?
A dispensary, pharmacy, medical program, B2B supply chain, service center and textile mill are not variations of the same channel.
What may be claimed?
Research interest, laboratory data, state authorization and FDA approval do not create the same evidentiary or promotional rights.
Who else is affected?
Patients, communities, regulators, employees, investors, law enforcement, policymakers, physicians, scientists and industry partners can all matter.
The Regulated-Market Map
A plant does not arrive with a business model attached to it.
Biology creates possibilities. Law, processing, science, licensing and customer demand decide which possibilities become real businesses.
Licensed Medical Cannabis
Cultivation, processing and dispensing can operate inside state medical-marijuana systems with patient eligibility, physician participation, product rules and regulatory reporting.
State Adult-Use Markets
States can authorize nonmedical cannabis under state law, while federal treatment and individual state rules remain distinct from medical frameworks.
Industrial Hemp
Fiber, hurd, grain, seed and other non-cannabinoid applications connect agriculture to processing, materials, textiles, construction and manufacturing.
Laboratories & Science
Analytical testing, cannabinoid chemistry, research, clinical development and scientific instrumentation create technical markets where evidence is part of the product.
Ancillary Technology
Greenhouse systems, HVAC, lighting, irrigation, sensors, automation, software, packaging and manufacturing equipment can serve regulated operators without being cannabis products themselves.
Policy & Institutions
Trade associations, research organizations, public agencies, attorneys, advocates and policymakers shape the rules and public understanding around regulated markets.
Hemp can end up in fiber. Medical marijuana can enter a licensed dispensing system. A cannabinoid can enter drug development. Those are different commercial architectures, not branding variations.
Federal Cannabis Law in 2026
The federal picture changed materially in April. It did not suddenly become simple.
On April 28, 2026, the Department of Justice and DEA placed FDA-approved marijuana-containing drug products and marijuana covered by qualifying state medical-marijuana licenses into Schedule III of the Controlled Substances Act. The final rule also established federal requirements affecting handling, registration, records and import-export controls for covered products.
Other marijuana remains Schedule I under that final rule. DEA also continued a separate rulemaking process concerning broader marijuana rescheduling. As of August 27, 2026, DEA's public rescheduling materials document the hearing process that began June 29, 2026, rather than a separate final rule placing all marijuana into Schedule III.
The distinction matters. “Marijuana is Schedule III now” is too broad. “Nothing changed federally” is also wrong.
Current federal sources: April 28, 2026 Federal Register final rule and DEA marijuana rescheduling regulatory actions.
Florida Medical Marijuana
Florida is a large medical-marijuana market built around vertical integration.
Florida's medical system is especially useful as a commercial example because agriculture, processing, healthcare, retail and state regulation sit inside one vertically integrated operator model.
The Florida Office of Medical Marijuana Use states that medical marijuana treatment centers, or MMTCs, are the businesses authorized by the state to cultivate, process and dispense low-THC cannabis and medical marijuana. That means a Florida MMTC brand is not merely a storefront brand. Production decisions made months earlier can eventually affect menu availability, product consistency and the patient experience.
Current Florida source: Florida Office of Medical Marijuana Use weekly updates. The August 21, 2026 update is the current weekly report as of this page revision.
Cannabis as Agriculture
Regulation changes the business model. It does not repeal photosynthesis.
Before cannabis becomes a package, a menu item or a regulated product, it is a crop responding to genetics, roots, water, light, humidity, nutrition, pests, disease pressure and people.
Genetics & Propagation
Seed, clonal material, mother stock, tissue culture and breeding programs influence plant identity, uniformity, crop behavior and what can be reproduced commercially.
Environment
Temperature, humidity, airflow, light and carbon dioxide can affect plant performance, facility requirements and disease pressure.
Root Zone
Water quality, media, irrigation, fertility and root health connect plant biology to operating discipline.
Plant Health
Sanitation, integrated pest management, clean material and biosecurity affect yield, quality, testing risk and production continuity.
Labor & Automation
Controls and automation can reduce repetitive work, but skilled crop judgment remains valuable in highly managed environments.
Economics
Yield, crop loss, energy, labor, facility cost, testing, inventory and market price eventually meet in the same P&L.
For the deeper greenhouse, lighting, climate, hydroponic, water and environmental-control side of the market, see my Controlled-Environment Agriculture, Greenhouse & Vertical Farm work. The broader crop and agribusiness relationship sits within Agriculture & Farming.
“Premium cultivation” is marketing language. A production system capable of delivering it repeatedly is the evidence.
Genetics, Breeding & Propagation
The product story often begins long before anybody gives the finished product a name.
Commercial production depends on plant identity, healthy source material and enough consistency for the business to reproduce what it promises. Genetics can influence morphology, chemistry, production behavior and how operators think about differentiation.
Cannabis consumer language often uses “strain.” Breeders and scientists may use cultivar, chemotype, chemovar or more precise identifiers depending on context. I am less interested in policing vocabulary than making sure the organization knows what it means when it uses it.
Commercial Cultivation Systems
Indoor, greenhouse and outdoor cannabis are different operating models.
The facility changes capital intensity, environmental control, energy use, weather exposure, labor requirements and production economics. Those realities eventually shape how a company should position capability and what it can credibly promise.
The commercial story should explain why the production system matters to quality, reliability, cost, product availability or the buyer. “High tech” is not a value proposition by itself.
Processing & Manufacturing
Harvest is where agriculture starts handing the product to manufacturing.
Post-harvest handling, drying, curing, storage, licensed extraction, formulation, packaging, batch traceability, quality systems and testing can determine whether biological material becomes a consistent commercial product.
That creates a useful bridge between cannabis and broader industrial strategy. Facility capability affects what can be manufactured, how consistently it can be produced, which buyers will trust it and where margin can exist.
For organizations selling equipment, processing systems, automation or industrial capability into the sector, my broader Manufacturing & Industrial B2B work provides the adjacent commercial framework.
Cannabis Testing & Analytical Laboratories
The laboratory is where a marketing claim eventually meets an instrument.
Analytical science connects cultivation, manufacturing, safety, compliance and customer trust. The test panel and exact requirements vary by jurisdiction, but cannabis laboratories commonly work across cannabinoid analysis and regulated contaminant testing.
Cannabinoids
Quantitation supports composition reporting and regulated product information.
Microbiology
Testing may address specified microorganisms and contamination risks.
Pesticides & Metals
Jurisdictions can establish limits for pesticide residues and environmental contaminants.
Solvents & Mycotoxins
Processed products and regulated panels may require additional analytical controls.
Certificates of analysis communicate results, but a number still requires context. Sampling, methods, validation, calibration, quality systems and the rules of the market determine what the result actually means.
For deeper laboratory commercialization, diagnostics, lab technology, instrumentation and technical search strategy, see Diagnostics, Laboratories & Clinical Research Marketing.
“30% THC” is a laboratory result. It is not a complete brand position.
Selling Cannabis in a Regulated Market
“Can this be sold online?” is not really a website question.
It is a jurisdiction, license, product, eligibility, fulfillment and payment question that eventually reaches the website.
Lawful cannabis commerce can involve physical dispensaries, online menus, reservations or ordering, pickup, delivery where authorized, patient or age eligibility, inventory integration, state tracking systems, payments, loyalty, messaging and third-party platform restrictions.
I do not assume that because a customer can browse a product online, the product can be shipped like a pair of shoes.
Industrial Hemp
Hemp is bigger than CBD.
Fiber, hurd, grain, seed and other non-cannabinoid applications make industrial hemp an agricultural and manufacturing story quite apart from dispensary cannabis.
USDA's Domestic Hemp Production Program provides the federal production framework. Producers must be licensed or authorized through the applicable state, tribal or USDA program. Downstream products can also involve FDA, state and local requirements depending on what the material becomes.
The commercial chain can include genetics, farming, retting, decortication, fiber preparation, quality classification, materials processing, manufacturing and B2B sales. The useful buyer may be a textile company, building-material manufacturer, composite business, animal-bedding company or another industrial customer that has nothing to do with dispensaries.
Current USDA reference: USDA Agricultural Marketing Service, Hemp Production. USDA currently notes that hemp producers need authorization through a state, tribal or USDA hemp program.
A Federal Hemp Change Coming November 12, 2026
The definition changes again, which means planning has to use the date as part of the strategy.
Federal legislation enacted in 2025 changes the statutory hemp definition effective November 12, 2026. The revised framework uses a total-THC concept that includes THCA and includes exclusions affecting some cannabinoid products, while explicitly recognizing industrial hemp for non-cannabinoid uses.
This matters to companies whose product classification, sourcing, inventory or marketing depends on the current definition. A strategy that is viable in August may need to be evaluated again before November.
I use regulatory context to ask better business and communication questions. Product-specific classification and legal conclusions belong with qualified counsel and regulators.
Background reference: Congressional Research Service, Changes to the Statutory Definition of Hemp and Issues for Congress, together with current USDA hemp-production guidance.
Medical Cannabis & Patient Communication
The word “medical” should raise the standard of communication.
Patients may be making decisions while living with pain, cancer, epilepsy, PTSD or other serious health concerns. That deserves more care than ordinary lifestyle branding.
Patient education should explain the applicable program, eligibility, product categories, practical steps and approved information without turning marketing copy into individualized medical advice. State authorization also does not automatically create an FDA-approved therapeutic claim.
FDA says it has approved one cannabis-derived drug product and three synthetic cannabis-related drug products, while it has not approved cannabis itself for the treatment of any disease or condition. FDA also continues to act against unapproved cannabis-derived products marketed with unlawful therapeutic claims.
Current FDA references: FDA Regulation of Cannabis and Cannabis-Derived Products and FDA warning letters for cannabis-derived products.
Psychedelics, Psilocybin & Emerging Natural-Medicine Markets
Research, state service models and drug development are moving on different tracks.
Psychedelic research has generated serious scientific and commercial interest, but research interest is not blanket approval. FDA finalized its Psychedelic Drugs: Considerations for Clinical Investigations guidance in July 2026 for sponsors developing psychedelic drugs for medical conditions, including psychiatric and substance-use disorders.
At the same time, state-regulated access models can be structurally different from cannabis. Oregon regulates licensed psilocybin service centers and facilitators. Colorado's natural-medicine framework has its own rules and does not simply reproduce a dispensary model.
A pharmaceutical sponsor, university research program, licensed state service center and consumer “psychedelic brand” should not be described as though they were the same business.
Trade Associations, Public Policy & Institutional Communication
Regulated markets are built in legislatures, agencies, laboratories, farms and storefronts at the same time.
Cannabis policy can involve trade associations, businesses, regulators, researchers, attorneys, patient groups, public-health organizations, law enforcement, employers, advocates and communities. Those stakeholders do not share one objective, and good communication should not pretend they do.
I can help organizations make public policy easier to understand, structure issue content, communicate member value, build digital authority, explain research and create useful stakeholder journeys. I do not provide legal advice, represent myself as a registered lobbyist or make lobbying-disclosure determinations.
When the organization itself is the market institution, my Trade Association Consultant & Advisor work goes deeper into membership, advocacy, industry research, events, sponsorship and long-term relevance.
Law Enforcement, Corrections & Reform
A new legal market can exist while people are still living with the consequences of an older legal regime.
Legalization and medical access can change enforcement, training, possession rules, impaired-driving questions, licensing verification and public communication. Reform discussions can also involve pardons, expungement, sentencing, reentry, employment and how jurisdictions treat conduct that is now legal or regulated differently.
Those issues are important, but they are not the commercial center of this page. I include them because regulated markets affect institutions and communities, and because policy communication becomes less trustworthy when it treats public safety or human consequences as somebody else's problem.
For an agency, nonprofit, policy institute or legal organization, the audience and objective may be recruitment, public information, donor support, employer partnerships, research visibility or access to legal services rather than consumer demand.
Cannabis Science, Research & Drug Development
Cultural enthusiasm can move quickly. Clinical evidence usually insists on taking longer.
THC, CBD, minor cannabinoids, terpenes, the endocannabinoid system and psychedelic compounds remain active areas of scientific interest. That interest spans pharmacology, formulation, diagnostics, toxicology, clinical trials, data, manufacturing and regulatory review.
A molecule can be promising without being approved. A preclinical finding can be important without being a patient claim. A laboratory result can be precise without proving a therapeutic outcome.
This is where my broader Pharmaceutical, Biotechnology & Life Sciences and Science Marketing work becomes useful.
Trust & Responsible Communication
Normalizing a lawful business does not require pretending the category has no risks.
Mature regulated markets earn trust by behaving like mature markets. That means protecting minors, respecting evidence, using accurate labels, treating medical and customer data carefully, keeping regulatory information current, communicating recalls or testing problems responsibly and avoiding claims that outrun what the evidence supports.
Protect Minors
Youth targeting should be treated as a serious compliance and public-trust issue.
Respect Evidence
Research interest should not be translated into therapeutic certainty before the evidence exists.
Use Accurate Labels
Product identity, chemistry, hemp status, materials and regulated claims benefit from precision.
Own Problems
Recalls, testing issues and compliance failures need disciplined communication rather than brand theater.
Trust gets more valuable as the number of disclaimers on the category gets longer.
Marketing & Commercial Growth
I work from the business outward.
A cultivator, vertically integrated MMTC, hemp-fiber processor, testing laboratory, research organization and trade association do not need variations of the same campaign.
One may need wholesale demand. One needs qualified patients. One needs industrial buyers. One needs research partners. One needs members and policymakers. The marketing system should reflect the actual business rather than forcing every organization into the same channel list.
Positioning & Market Clarity
Define the lawful product, audience, business model, differentiation and proof before creating more promotion.
Technical Content & Authority
Translate cultivation, manufacturing, laboratory, scientific or policy complexity without making the organization sound generic.
B2B Demand & Partnerships
Build visibility and sales support for processors, laboratories, equipment companies, industrial hemp businesses and other account-driven markets.
Public & Stakeholder Communication
Help associations, research groups and regulated organizations make issues, evidence and institutional roles easier to understand.
Fractional CMO & Advisory
Provide senior outside perspective when strategy, marketing, sales, partnerships, technology and leadership decisions need to stay connected.
Brand, Digital & Customer Growth
For deeper cannabis branding, websites, SEO, AI discovery, advertising strategy, content, social and customer acquisition, continue to the Cannabis Marketing Agency & Consultant page.
SEO · GEO · AEO · AI Search
Regulated markets punish sloppy entity architecture.
“Cannabis” can refer to a plant, a medical program, a controlled substance, an industrial crop, a research subject or a consumer category. Search engines and AI systems need enough context to understand which one the website means.
A useful cannabis information chain can look like: operator → license → jurisdiction → facility → product → testing → eligible customer → lawful channel.
A useful hemp chain can look like: producer → production authorization → crop purpose → material → processing → specification → industrial buyer.
A useful research chain can look like: compound → sponsor → clinical investigation → indication → evidence status → regulatory status.
That is central to my AI Search & Organic Growth work. The goal is not to write for robots. The goal is to make the organization and its real-world relationships clear enough that humans and machines can retrieve the right answer.
Measurement
Measure the business the license, facility and mission actually allow you to operate.
| Metric | What It Shows | Why It Matters |
|---|---|---|
| Revenue per Location | Commercial productivity of licensed retail locations. | Expansion only works when unit economics work. |
| Same-Store Growth | Performance of mature locations over time. | Separates real operating growth from simply adding stores. |
| Repeat Purchase or Visit Rate | Customer or patient return behavior. | Measures retention, experience and product fit. |
| Inventory Turn | How quickly regulated inventory moves. | Inventory still ties up capital even when demand is strong. |
| Stock-Out Rate | Availability gaps in demanded products or categories. | Demand generation does not help when the item is missing. |
| Testing Failure Rate | Batches failing required analytical criteria. | Failure creates cost, supply and reputation consequences. |
| Yield / Production Efficiency | Commercial output relative to facility inputs. | Marketing cannot permanently outrun poor production economics. |
| Qualified B2B Pipeline | Processor, manufacturer, lab or institutional opportunities. | Industrial and scientific markets are account-driven. |
| Member Retention | Trade-association members renewing. | Policy relevance should create durable member value. |
| Research Engagement | Qualified scientific, clinical, partner or funding interest. | Research organizations need more than consumer attention. |
| Organic Search Visibility | Discovery across relevant legal and commercial intent. | Owned visibility matters when paid channels are constrained. |
| AI Search Accuracy | Whether AI systems correctly understand the organization and context. | Regulatory misinformation can be worse than no visibility. |
Frequently Asked Questions
Cannabis, Hemp & Regulated Markets FAQ
What does a cannabis and regulated-market marketing consultant do?
I help lawful cannabis cultivators, medical marijuana treatment centers, dispensary organizations, hemp companies, laboratories, genetics businesses, technology companies, trade associations and related organizations improve positioning, websites, search visibility, technical communication, stakeholder strategy and commercial growth.
Is Paper Boat Media a cannabis marketing agency?
Paper Boat Media can serve clients searching for cannabis marketing agency help, but the working model is consultant-led. Clients work directly with me as a strategist, advisor and fractional marketing leader. The dedicated Cannabis Marketing Agency & Consultant page covers branding, digital marketing, SEO, advertising strategy, content and customer growth in more depth.
Did all marijuana become Schedule III in 2026?
No. The April 28, 2026 federal final rule placed FDA-approved marijuana-containing drug products and marijuana covered by qualifying state medical-marijuana licenses into Schedule III. Other marijuana remains Schedule I under that final rule, while a separate broader rescheduling rulemaking has continued through DEA.
What changed with Section 280E?
The April 2026 final rule states that qualifying state medical-marijuana licensees are no longer subject to the deduction disallowance in Internal Revenue Code Section 280E because that provision applies to trafficking in Schedule I or II controlled substances. The rule also says this is not an individual tax determination, so businesses should obtain qualified tax advice for their own circumstances.
How does Florida's medical marijuana market work?
Florida licenses vertically integrated medical marijuana treatment centers, or MMTCs, that operate within the state's medical-marijuana system. Cultivation, processing and dispensing are connected inside the MMTC framework rather than being treated as completely separate standalone license categories.
How large is Florida's medical marijuana program?
The Florida OMMU August 21, 2026 weekly update reported 939,639 active qualified-patient cards and 776 approved dispensing locations statewide. Those figures are a dated regulatory snapshot and should be rechecked when current counts matter.
Why does cannabis belong within agriculture?
Cannabis cultivation involves genetics, propagation, environmental management, irrigation, fertility, pest and disease management, labor, harvesting and post-harvest handling. Regulation is unusual, but the crop remains biological.
What is the difference between indoor, greenhouse and outdoor cannabis cultivation?
The systems differ in environmental control, capital intensity, energy use, weather exposure, facility requirements, labor and production economics. Those differences can affect consistency, cost, crop risk and the commercial story.
Why do genetics and propagation matter to cannabis marketing?
Genetics and source material influence production behavior, identity and repeatability. If a company makes claims around a cultivar, chemistry or product experience, the production system needs enough consistency to support the promise.
What does a cannabis processor or manufacturer need from marketing?
Processors often need to translate post-harvest capability, extraction, formulation, quality systems, traceability, manufacturing capacity and testing into a commercial reason for partners or buyers to trust the operation.
Why are cannabis testing laboratories important to brand trust?
Laboratory testing connects composition, contamination controls, regulatory release and product information. The value of a result depends on sampling, methods, quality systems and the applicable rules, not simply on a number printed on a certificate.
Can cannabis be sold online?
Digital browsing, ordering, pickup or delivery can be available in some lawful markets, but the exact model depends on jurisdiction, product, license, eligibility, fulfillment, payment and local rules. A website cannot create permission the license does not provide.
What is industrial hemp?
Industrial hemp refers to cannabis used for non-cannabinoid agricultural and industrial purposes such as fiber, hurd, grain and seed-derived materials within the applicable legal framework. It can feed textile, composite, building-material and other manufacturing markets.
How is hemp different from marijuana marketing?
Hemp and marijuana can share plant biology while operating in different product, regulatory and buyer systems. Industrial hemp may sell to manufacturers or materials companies, while medical marijuana may be distributed through a licensed patient system. The audience and commercial logic can be entirely different.
What changes for federal hemp law on November 12, 2026?
A revised federal hemp definition is scheduled to take effect November 12, 2026. Among other changes, it uses a total-THC concept including THCA and creates exclusions affecting certain cannabinoid products while recognizing industrial hemp for non-cannabinoid uses. Businesses should use qualified legal and regulatory counsel for product-specific determinations.
Does FDA approve cannabis medical claims?
FDA has not approved cannabis itself for the treatment of any disease or condition. FDA has approved one cannabis-derived drug and three synthetic cannabis-related drug products. Product-specific claims should be based on the actual regulatory and evidentiary status rather than general research interest.
Can CBD products be marketed with therapeutic claims?
Unapproved CBD products should not be marketed as though FDA has approved them to diagnose, treat, cure, mitigate or prevent disease. FDA continues to publish warning letters involving cannabis-derived products and unapproved therapeutic claims.
Why include psychedelics on a cannabis and regulated-markets page?
Psychedelics are not cannabis, but they illustrate the same strategic lesson: a controlled substance, research compound, state-regulated service and future pharmaceutical product can have very different legal and commercial structures. That distinction matters when organizations use broad “natural medicine” language.
Did FDA approve psychedelic drugs in July 2026?
No. FDA finalized guidance for clinical investigations of psychedelic drugs in July 2026. Guidance for drug development is not approval of every psychedelic product or therapeutic claim.
Do you work with cannabis trade associations and policy organizations?
Yes. I can help with association positioning, member communication, public education, research visibility, stakeholder journeys, digital issue architecture, thought leadership and AI/search authority. I do not provide lobbying-disclosure legal advice or represent myself as a registered lobbyist.
Do you advise law-enforcement or reentry organizations on cannabis policy?
My role can include public information, recruitment, digital communication, stakeholder trust and strategy for organizations affected by changing cannabis policy. Legal interpretation, law-enforcement standards, sentencing, expungement and individual legal advice belong with the appropriate qualified authorities.
How should regulated companies approach SEO and AI search?
Websites should clearly identify the jurisdiction, legal market, license type, product category, evidence status, relevant dates and intended audience. Those relationships help humans and AI systems avoid confusing medical marijuana, adult-use cannabis, industrial hemp, scientific research and other regulated markets.
What does GEO mean for cannabis and hemp companies?
Generative Engine Optimization focuses on making information clear, attributable and retrievable in AI-driven search. In regulated markets, that usually means strong entity relationships, direct answers, current sources, explicit dates, accurate product identity and clear jurisdictional context.
Do you only work with cannabis companies in Florida?
No. I am based in Florida and can advise lawful cannabis, hemp, research, association, industrial and related regulated-market organizations across the United States and selected international markets where the assignment fits. Geography still matters because the legal and commercial environment can change significantly by jurisdiction.
Do you provide legal, medical, tax or regulatory advice?
No. My role is marketing, growth, communications, positioning, search and strategic consulting. Controlled-substance law, licensing, medical decisions, tax determinations, labeling approval, regulatory sign-off and other professional judgments should be handled by appropriately qualified professionals.
What is the best way to start a cannabis consulting engagement?
Bring me the actual challenge. Tell me what the organization is, what legal market it operates in, what it sells, who matters commercially, what is happening now and what you want to happen instead. That is usually more useful than starting with a request for a particular marketing tactic.
Talk With Rob
Bring me the regulated-market problem, especially if it refuses to stay inside one department.
Maybe the cultivation company has technical credibility and no wholesale demand. Maybe the MMTC is growing locations faster than brand clarity. Maybe the hemp business has a product-classification question coming before November. Maybe a testing laboratory is excellent at science and invisible to operators. Maybe the association needs to explain a rule change without turning the website into a legal memo.
You do not need to diagnose which marketing tactic fixes it before contacting me. Tell me what is happening, what you want to happen instead and what constraints are real. I can work outward from there.
Call or text 407-227-0741
Email robert@paperboatmedia.com
Dr. Robert Urban
Paper Boat Media · DeLand, Florida